2.4. Monocyte Activation Test (MAT)

KG Katharina Gerling
LH Lisa Maria Herrmann
CS Christoph Salewski
MW Melanie Wolf
PM Pia Müllerbader
DS Dorothea Siegel-Axel
HW Hans Peter Wendel
CS Christian Schlensak
MA Meltem Avci-Adali
SS Sandra Stoppelkamp
request Request a Protocol
ask Ask a question
Favorite

The MAT was performed with human whole blood as described before [15]. Briefly, the cotton or synthetic swabs (untreated or pyrogen-impregnated) were placed in sterile 2 mL DNA LoBind Eppendorf reaction tubes, and 1.5 mL of 1:10 diluted pooled human whole blood was added and incubated for 18 h at 37 °C. Increasing 2-fold concentrations from 0.0125 to 0.5 EU/mL LPS (concentrations correspond to the volume in the incubation to enable a comparison to a solid swab material) were added to the diluted blood to detect the immune activation potential of the pooled blood to pyrogens (standard dilution row). A concentration of LPS in the middle of the used standard curve (0.1 EU/mL) served as liquid LPS spike and as the lower concentration for LPS impregnation of the swabs. Half of the sterile, non-impregnated swabs were spiked with liquid LPS directly at the time of incubation (yielding 0.1 EU/mL in the incubation) to detect potential interferences with the swabs. The LPS-impregnated samples (0.1 EU/mL and 1.0 EU/mL) were incubated with blood under the same conditions as the sterile swabs.

After the incubation, the samples were centrifuged at 300 g for 5 min, and the supernatant was analyzed for cytokine secretion by enzyme-linked immunosorbent assay (ELISA). Cytokine production triggered by the abdominal swabs was measured by ELISA (human IL1β Duo-Set; R&D Systems/BioTechne, Wiesbaden, Germany) according to the manufacturer’s instructions. The quantification of secreted IL1β was performed using Gen5 software (Biotek, Bad Friedrichshall, Germany).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A